Nasdaq · CIK 0000882095 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
GILEAD SCIENCES, INC.
GILD chart by TradingView
PRICE HISTORY
LIVE · NASDAQGILD chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $29.4B
- EBITDA
- $12.8B
- FREE CASH FLOW
- $9.5B
- EPS
- $6.78
- GROSS MARGIN
- 78.83%
- ROIC
- —
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
+170%7.0x827.8x
⤢
P / SALES (TTM)
5.2x
+54%2.7x5.9x
⤢
P / BOOK
13.3x
+111%3.7x13.3x
⤢
EV / EBITDA (TTM)
—
+113%6.2x21.0x
⤢
EV / REVENUE (TTM)
—
+20%3.6x5.1x
⤢
FCF YIELD (TTM)
8.24%
-9.3pp5.85%17.52%
⤢
DIVIDEND YIELD (TTM)
2.55%
+0.3pp2.28%4.81%
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$7.8B
+4%⤢
EBITDA (DERIVED)
$-10.3B
-332%⤢
NET INCOME
$-10.5B
-415%⤢
EPS (DILUTED)
$-8.44
-440%⤢
REVENUE GROWTH YOY
10.18%
+19.8pp-21.78%26.23%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
44.00%
-11.9pp10.17%55.93%
⤢
RETURN ON CAPITAL
—
-33.0pp0.28%44.17%
⤢
RETURN ON EQUITY (TTM)
-27.39%
-116.8pp-27.39%89.38%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN79.76%
OPERATING MARGIN-133.21%
NET MARGIN-134.51%
FCF MARGIN44.00%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$3.4B
-18%⤢
STOCK-BASED COMP
$0.2B
+143%⤢
CAPITAL EXPENDITURE
$0.1B
-29%⤢
SHARES OUTSTANDING
1.24B
-7%⤢
DIVIDEND / SHARE
$0.82
+74%BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
—
-45%⤢
TOTAL DEBT
$26.2B
-3%⤢
DEBT / EBITDA (TTM)
95.8x
+6759%1.4x95.8x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 92.80%INSIDERS 0.11%OTHER / RETAIL 7.09%3,054 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 9.59% | 119.0M | $15.85B | -3.4% |
| Vanguard Capital Management LLC | 6.50% | 80.7M | $10.74B | NEW |
| FMR, LLC | 5.79% | 71.9M | $9.58B | +9.6% |
| State Street Corporation | 4.82% | 59.9M | $7.97B | -0.6% |
| Invesco Ltd. | 3.35% | 41.6M | $5.54B | -4.3% |
| Capital World Investors | 3.33% | 41.3M | $5.50B | -3.7% |
| Vanguard Portfolio Management LLC | 2.83% | 35.1M | $4.68B | NEW |
| JPMORGAN CHASE & CO | 2.74% | 34.0M | $4.53B | +47.6% |
| Geode Capital Management, LLC | 2.39% | 29.7M | $3.96B | +0.1% |
| Capital Research Global Investors | 2.18% | 27.1M | $3.61B | +7.2% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.